Ultragenyx Pharmaceutical Inc.

Ultragenyx Pharmaceutical Inc.RAREEarnings & Financial Report

Nasdaq · Health Care · Pharmaceutical Preparations

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

Top Holders

Holder% OwnedSharesChangeAs of
The Vanguard Group10.56%
8.7M
▲ +0.44pp2024-02-13
BlackRock, Inc.6.40%
5.2M
2024-01-29
Wellington Management Group LLP5.38%
4.4M
2024-02-08
Sands Capital Management, LLC5.00%
4.1M
2024-02-13
T. ROWE PRICE ASSOCIATES, INC.4.20%
3.5M
2024-02-14
RTW Investments, LP2.10%
2.0M
-6.30pp2024-11-14

Insider Transactions

Net 90d: $2.70M · buys $0 / sells $2.70M
Range:
Action:
Role:
InsiderRoleAction
2026-04-22Huizenga Theodore AlanSVP, Chief Accounting OfficerGrant
20.2K
$0.00$0
2026-04-16Parschauer Karah HerdmanEVP and Chief Legal OfficerGrant
28.9K
$0.00$0
2026-04-16Eric CrombezEVP and Chief Medical OfficerGrant
34.7K
$0.00$0
2026-04-16Erik HarrisEVP & Chief Commercial OfficerGrant
28.9K
$0.00$0
2026-04-16Pinion John RichardSee RemarksGrant
23.1K
$0.00$0
2026-04-16Huang Dennis KarlSee RemarksGrant
23.1K
$0.00$0
2026-04-16KAKKIS EMIL DPresident & CEOGrant
76.7K
$0.00$0
2026-04-16Howard HornChief Financial OfficerGrant
34.7K
$0.00$0
2026-04-01Howard HornChief Financial OfficerSell (open market)
4.7K
$20.97$98.2K
2026-03-10Parschauer Karah HerdmanEVP and Chief Legal OfficerSell (open market)
3.5K
$22.67$79.5K
110 of 28
Page 1 / 3